

# Charles T. Mehlman, DO, MPH

## **Current Practice/Center/Institution:**

Professor, Pediatrics and Pediatric Orthopaedic Surgery / Director, Musculoskeletal Outcomes Research / Co-Director, Brachial Plexus Center  
Co-Director, Legg-Calve-Perthes Center / Cincinnati Children's Hospital Medical Center

## **Medical School & Graduation Year:**

DO: Ohio University College of Osteopathic Medicine, 1989.  
MPH: Harvard School of Public Health, 1998.

## **Place of Orthopaedic Residency and Fellowship Training:**

Residency: Internal Medicine, Northeastern Ohio Universities College of Medicine, Akron General Medical Center, Akron, OH; 1990-1991

Orthopaedic Surgery, Ohio University College of Osteopathic Medicine, Grandview Hospital and Medical Center, Dayton, OH, 1991-1995.

Fellowship: Pediatric Orthopaedic Surgery, University of Cincinnati College of Medicine, Children's Hospital Medical Center, Cincinnati, OH, 1995-1996

MPH, Clinical Effectiveness and Outcomes Research, Harvard School of Public Health, Boston, MA, 1996-1998.



## **What attracted your interest to IPSG?**

As a resident and fellow I was strongly influenced by Richard Bowen, MD at the Alfred I. duPont Hospital for Children and Alvin H. Crawford, MD at Cincinnati Children's. Legg-Calve-Perthes disease is the most common hip disease that strikes children AND a major cause of hip arthritis in kids. The IPSG is aimed at leveraging world-wide brainpower to combat L-C-P.

## **What would you say is the most challenging part of treating Perthes Disease?**

I think that the most challenging part of treating patients with Legg-Calve-Perthes disease is not setting our treatment goals high enough. L-C-P is at times still discussed as a "self-limiting disorder" AND as a "non-surgical disease". I think that our goal should be to "cure the disease" and produce as many normal hips as we possibly can.

## **What would you like to see accomplished through annual IPSG meetings?**

It is my hope that through the efforts of the IPSG our future L-C-P patients will benefit from new knowledge gained from prospective clinical trials and randomized clinical trials. Only in this evidence-based manner can we identify the best possible ways to treat our L-C-P patients.

## **Read more about Dr. Mehlman here!**

